About 13 results found for searched term "Farnesoid X Receptor" (0.122 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M3775 | Obeticholic Acid (INT-747) | Farnesoid X Receptor |
| 6-ECDCA; UNII-0462Z4S4OZ; OCA; 6-Ethylchenodeoxycholic acid | ||
| Obeticholic Acid (INT-747) is a potent, orally active, selective farnesoid X receptor (FXR) agonist with an EC50 of 99 nM.May be used in studies related to non-alcoholic steatohepatitis (NASH). | ||
| M6201 | Tropifexor | Farnesoid X Receptor |
| LJN452 | ||
| Tropifexor is a novel and highly potent agonist of farnesoid X receptor (FXR). | ||
| M6302 | Fexaramine | Farnesoid X Receptor |
| Fexaramine is a selective farnesoid X receptor (FXR) agonist with EC50 of 25 nM, with 100-fold increased affinity relative to natural compounds. | ||
| M8582 | NDB | Farnesoid X Receptor |
| NDB is a selective antagonist of human Farnesoid X receptor α (FXRα) that effectively modulates FXRα down-stream genes. | ||
| M9039 | Cilofexor | Farnesoid X Receptor |
| GS-9674; PX-104 | ||
| Cilofexor is a potent, selective, orally active non-steroidal farnesoid X receptor (FXR) agonist with an EC50 value of 43 nM. It has anti-inflammatory activity and may be studied in primary sclerosing cholangitis (PSC) and non-alcoholic steatohepatitis (NASH). | ||
| M9111 | Nidufexor | Farnesoid X Receptor |
| LMB-763 | ||
| Nidufexor is a farnesoid X receptor (FXR) agonist. | ||
| M9597 | Vonafexor | Farnesoid X Receptor |
| EYP001 | ||
| Vonafexor is a farnesoid X receptor agonist. | ||
| M10251 | Gly-β-MCA | Farnesoid X Receptor |
| Glycine-β-muricholic Acid | ||
| Gly-β-MCA is a potent, stable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor. | ||
| M21058 | BMS-986339 | Farnesoid X Receptor |
| BMS-986339 is an oral farnesoid X receptor (FXR) agonist being developed for nonalcoholic steatohepatitis (NASH). | ||
| M22512 | EDP-305 | Farnesoid X Receptor |
| EDP305 | ||
| EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 can be used for the research of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). | ||
| M28227 | Vidofludimus hemicalcium | DHODH |
| 4sc-101 hemicalcium; SC12267 hemicalcium | ||
| Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR. | ||
| M39141 | Nelumol A | Farnesoid X Receptor |
| Nelumol A is a farnesoid X receptor (FXR) agonist. | ||
| M42371 | Tauro-α-muricholic acid sodium | Metabolite/Endogenous Metabolite |
| Tauro-α-muricholic acid (T-α-MCA) sodium is a FXR (Farnesoid X receptor) antagonist (IC50=28μM). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
